Latest Healthcare News

Sigma Healthcare will release its FY26 full year results on 27 August, unveiling a new segment reporting structure dividing Australia and International operations. The update aims to clarify performance amid ongoing international growth and merger integration.

ResMed Inc. posted a 10% rise in fiscal 2026 revenue to $5.65 billion, bolstered by the acquisition of Noctrix Health and an agreement to sell its MatrixCare business. The company continues to invest in AI-powered digital health solutions amid ongoing patent litigation and a shifting regulatory landscape.

Green Cross Health CEO Rachael Newfield will step down in January 2027 following the sale of the Medical division, paving the way for a new pharmacy-centric leadership role.

Austco Healthcare has completed the $2.24 million acquisition of Medical Communications Systems, transitioning its long-term South Australian reseller into a direct sales operation to deepen market engagement.

Proteomics International has achieved a key patent acceptance in Australia for its PromarkerEndo blood test, reinforcing its intellectual property portfolio and commercialisation strategy in a major healthcare market.

Pro Medicus’ US subsidiary Visage Imaging has landed a 7-year, A$23 million contract to deploy its cloud-based Visage 7 platform across St. Luke’s Health System, marking a further expansion in North America.

Anteris Technologies posted a $51.7 million loss in H1 2026 amid ramped-up R&D and clinical trial activity, supported by a $320 million capital raise and Medicare reimbursement for its DurAVR heart valve trial.

EBR Systems marked a commercial milestone with over 100 WiSE CRT implants and secured purchasing agreements with three major US healthcare networks. The company is progressing toward Medicare coverage and scaling manufacturing, supported by a near-complete A$150 million capital raise.

Enlitic has launched its cloud-based Ensight platform in the US through a phased deployment with Radiology Imaging Associates, generating an initial annual recurring revenue of approximately US$50,000 and setting the stage for broader expansion.

LTR Pharma reports a 93% response rate in men seeking convenience and spontaneity with SPONTAN, alongside a 64% response in post-prostatectomy patients, highlighting potential for its rapid-onset intranasal ED treatment in challenging populations.

ReNerve Limited has gained marketing approval for its flagship NervAlign Nerve Cuff in India, marking a critical milestone in its global expansion and enabling commercial rollout in one of the world's largest nerve repair markets.

Integral Diagnostics (ASX: IDX) posted strong preliminary FY26 results with revenue nearing $790 million and operating EBITDA up 30%, while announcing Jenny Martin as incoming CFO amid leadership transitions.